Statins and bone: Myth or reality?

Calcified Tissue International

Volumn 69, Issue 2, 2001, Pages 63-66

  Edwards, C J ^a   Russell, R G G ^b   Spector, T D ^c  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; FRACTURE; HYPERCHOLESTEROLEMIA; OSSIFICATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; BONE AND BONES; BONE DENSITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID;

EID: 0034890845     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-001-2017-7     Document Type: Review

References (25)

1. Oral statins and increased bone-mineral density in postmenopausal women
2. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
3. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
4. HMG-CoA reductase inhibitors and the risk of fractures
5. Stimulation of bone formation in vitro and in rodents by statins
6. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
7. Statin use, bone mass and fracture: An analysis of two prospective studies
8. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients
9. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes
10. Cerivastatin increases BMP-2 expression in vivo and bone formation in concentrations of two orders of magnitude lower than other statins
11. Effects of one year treatment with statins on bone mass and metabolism
12. Statin use and bone mineral density (BMD) in older women: The Women's Health Initiative Study (WHI-OS)
13. No clinically relevant effect of fluvastatin on postmenopausal bone remodeling
14. Does statin use reduce risk of fracture in postmenopausal women? Results from the women's health initiative study (WHI-OS)
15. Use of statins and risk of fractures
16. Effect of pravastatin on fracture incidence in the lipid study: A randomised controlled trial
17. Effect of pravastatin on fracture incidence in the lipid study: Secondary analysis of a randomised controlled trial
18. Bisphosphonates. From the laboratory to the clinic and back again
19. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
20. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
21. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
22. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
23. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells
24. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
25. Dermal application of lovastatin to rats causes greater increases in bone formation and plasma concentrations than when administered by oral lavage